Investing
The company will use the funds to accelerate the development of its Ellipse Spinal Cord Stimulator Platform, used to treat chronic pain.
Tuva's CEO told MobiHealthNews that the company operates by "open-sourcing" the specialized knowledge needed to transform healthcare data and embedding that knowledge into an analytics-ready data model.
The company will fund and develop companies that focus on eight key areas in healthcare and create AI/genAI technologies that help advance those areas.
The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.
The Series B extension brings the round to $35 million, raising Hyro's total funding to $50 million.
The company will use the funds to accelerate the commercialization of its TAPS therapy and enhance the visibility of its offerings among providers and patients.
Former HealthTap employees allege that Mohr Davidow Ventures and company leaders stripped them of equity to position the company for a profitable turnaround benefiting MDV.
The company will use the funds to expand its commercial growth and clinical-evidence generation.
The company aims to empower physicians with job transparency, financial tools and a peer community to enhance workplace fulfillment and autonomy.
The company will use the funds to support its ongoing clinical trial, ramp up production and sales for its OtoSight Middle Ear Scope and relocate its headquarters.